Browse > Article
http://dx.doi.org/10.7314/APJCP.2016.17.3.1019

Proactive Consultation by a Clinical Pathologist Prevents Diagnostic Delay in Hematological Malignancies  

Chang, Chih-Chun (Department of Clinical Pathology, Far Eastern Memorial Hospital)
Su, Ming-Jang (Department of Clinical Pathology, Far Eastern Memorial Hospital)
Ho, Jung-Li (Department of Clinical Pathology, Far Eastern Memorial Hospital)
Sun, Jen-Tang (Department of Emergency, Far Eastern Memorial Hospital)
Tsai, Huang-Wen (Department of Surgery, Far Eastern Memorial Hospital)
Tang, Hui-Fei (Department of Clinical Pathology, Far Eastern Memorial Hospital)
Chu, Fang-Yeh (Department of Clinical Pathology, Far Eastern Memorial Hospital)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.17, no.3, 2016 , pp. 1019-1022 More about this Journal
Abstract
Background: Diagnostic difficulties in hematological malignancies may lead to unacceptably prolonged help-seeking to diagnostic interval as well as increased complications and poor outcomes. Proactive consultation by a clinical pathologist (PCCP) may help clinical diagnosis and therapeutic strategy. Hence, the aim of this investigation was to evaluate the effect of PCCP on the help-seeking to diagnostic interval in hematological cancer cases. Materials and Methods: From January to November, 2015, abnormal results of hematological laboratory testing with added laboratory comment were selectively screened out, and patients with such abnormalities in hematological laboratory testing and accompanied laboratory comment with PCCP were enrolled. Results: A total of 125 aberrant results of hematological laboratory testing were given with accompanied laboratory comments with PCCP and 40.8% (n=51) of these patient-oriented comments had an effect on clinical diagnosis and therapeutic strategy. Twelve of the subjects belonged to newly diagnosed hematological malignancies with the assistance of PCCP, and the help-seeking to diagnostic interval was also shortened from 42 days to 26 days in chronic lymphoid leukemia (CLL), from 83 days to 11 days in multiple myeloma (MM), and from 128 days to 15 days in myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN). During the monitoring interval, neither complication events nor deaths were reported in the study group. Conclusions: It was seemingly that PCCP prevented diagnostic delay in hematological malignancies via shortening the help-seeking to diagnostic interval, particularly in CLL, MM and MDS/MPN cases. PCCP can be considered to play an essential role in prompt establishment of diagnosis in hematological malignancies for those who newly present.
Keywords
Active laboratory consultation; proactive consultation by clinical pathologist; hematological malignancies;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Abdel-Rahman M, Stockton D, Rachet B, et al (2009). What if cancer survival in Britain were the same as in Europe: how many deaths are avoidable? Br J Cancer, 101, 115-24.   DOI
2 Elliss-Brookes L, McPhail S, Ives A, et al (2012). Routes to diagnosis for cancer - determining the patient journey using multiple routine data sets. Br J Cancer, 107, 1220-26.   DOI
3 Friese CR, Abel GA, Magazu LS, et al (2009). Diagnostic delay and complications for older adults with multiple myeloma. Leuk Lymphoma, 50, 392-400.   DOI
4 Howell DA, Smith AG, Roman E (2008). Help-seeking behaviour in patients with lymphoma. Eur J Cancer Care, 17, 394-403.   DOI
5 Howell DA, Smith AG, Jack A, et al (2013). Time-to-diagnosis and symptoms of myeloma, lymphomas and leukaemias: a report from the Haematological Malignancy Research Network. BMC Hematol, 13, 9.   DOI
6 Irfan SM, Bhurgri Y (2009). Clinico-pathological features and outcomes in chronic phase chronic myeloid leukemia patients treated with hydroxyurea. Asian Pac J Cancer Prev, 10, 591-94.
7 Kariyawasan CC, Hughes DA, Jayatillake MM, et al (2007). Multiple myeloma: causes and consequences of delay in diagnosis. QJM, 100, 635-40.   DOI
8 Kuwajima M (1997). Clinical laboratory consultation in the general hospital. Rinsho Byori, 45, 727-31.
9 Kuwajima M (1998). Active laboratory consultation for the clinical supporting system in the general hospital. Rinsho Byori, 46, 994-8.
10 Kyle RA, Gertz MA, Witzig TE, et al (2003). Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc, 78, 21-33.   DOI
11 Lyratzopoulos G, Neal RD, Barbiere JM, et al (2012). Variation in number of general practitioner consultations before hospital referral for cancer: findings from the 2010 national cancer patient experience survey in England. Lancet Oncol, 13, 353-65.   DOI
12 Lyratzopoulos G, Abel GA, McPhail S, et al (2013). Measures of promptness of cancer diagnosis in primary care: secondary analysis of national audit data on patients with 18 common and rarer cancers. Br J Cancer, 108, 686-90.   DOI
13 Summerfield GP, Carey PJ, Galloway MJ, et al (2000). An audit of delays in diagnosis and treatment of lymphoma in district hospitals in the northern region of the United Kingdom. Clin Lab Haematol, 22, 157-60.   DOI
14 Mai Y, Qi P, Xu Y, et al (2007). Clinical and laboratory features of newly diagnosed multiple myeloma: a retrospective, single-centre analysis. Chin Med J, 120, 1727-9.
15 Burke MD (1995). Clinical laboratory consultation. Clin Chem, 41, 1237-40.
16 Ong F, Hermans J, Noordijk EM, et al (1995). Presenting signs and symptoms in multiple myeloma: high percentages of stage III among patients without apparent myeloma-associated symptoms. Ann Hematol, 70, 149-52   DOI
17 Thomson CS, Forman D (2009). Cancer survival in England and the influence of early diagnosis: what can we learn from recent EUROCARE results? Br J Cancer, 101, 102-9.   DOI